layoffs, resignation

“As we invest to scale production of our commercial biomaterial products to meet expected demand in the United States and the Middle East, we are prioritizing our most promising cell therapy product candidates and programs and are rebalancing our workforce and identifying targeted expense reductions to support these priorities,” said CEO Robert J. Hariri.

Johnson & Johnson

The company is testing Carvykti in multiple myeloma patients, with a history of relapse, who have stopped responding to existing treatment and have received one to three prior therapies.

Merck flag

The FDA approved Merck’s Keytruda for the treatment of stage IB, II or IIIA non-small cell lung cancer after resection or platinum-based chemotherapy.

Sanofi

The companies announced today that the EU approval is indicated for treating children as young as 6 months old with severe atopic dermatitis.

European Medicines Agency

The application to the EMA was based on results from a late-stage study that showed the drug slowed down the rate of cognitive decline in patients with early Alzheimer’s by 27%, compared with a placebo.

AstraZeneca

The treatment is not expected to neutralize the currently dominant XBB.1.5 subvariant of Omicron.

marijuana cookies

Cannabis products, excluding Jazz Pharmaceuticals Plc’s epilepsy drug Epidiolex, are illegal at the federal level in the United States, although some states allow their use.

amoxicillin

Although nearly all the countries in Europe are reporting shortages, the EMA is not going to label the ongoing shortage of antibiotics in the continent a “major event”, according to a source familiar with the matter.

Hand, doctor, stop

Following the death of a patient, Magenta Therapeutics placed a hold on Phase I/II dose-escalation trial of its acute myeloid leukemia therapy.

Walgreens

Walgreens will prepare for the start of Automation Unit iA’s sale process around next month, according to Bloomberg, which cited sources who asked not to be identified as the matter is private.